Early Breast Cancer in Older Women May Not Require Radiotherapy
New research suggests that women 55 or older with stage one breast cancer displaying a speciﬁc biomarker pattern identifying the luminal A subtype can be effectively treated with just surgery and endocrine therapy. McMaster University researcher Dr Timothy Whelan presented research at the American Society of Clinical Oncology’s annual meeting in Chicago.
His research team, working with the Ontario Clinical Oncology Group at the Hamilton Health Sciences, tracked 501 patients with luminal A breast cancer for ﬁve years post-surgery and found the recurrence of cancer in the breast was just 2.3 per cent without radiotherapy. This was roughly comparable with a 1.9 per cent risk this patient sample had of developing a new breast cancer in their other untreated breast.
Whelan said at this time patients with early stage breast cancer typically undergo radiotherapy courses of three to ﬁve weeks to reduce the risk of their cancer recurring.
“These ﬁndings are exciting because we have identiﬁed a certain group of patients who can avoid radiotherapy and its associated side effects and potentially change for the better medical practice around the treatment of breast cancer,” said Whelan, a professor in the Department of Oncology at McMaster, a Canada Research Chair in Breast Cancer Research and a radiation oncologist for Hamilton Health Sciences.
“Radiotherapy has signiﬁcant early side effects, including fatigue and skin irritation that can last for several weeks after the course is completed, and late side effects such as breast shrinkage and distortion that can affect quality of life and very rarely more serious complications such as heart disease and second cancers,” he said.
“If we can avoid radiotherapy, so much the better. Not all cancers require the same level of often-invasive treatment. There is a very low risk group of breast cancers displaying the luminal A biomarker and they are not particularly aggressive.”
He said the overall risk of cancer recurrence following breast-conserving surgery has decreased in recent years thanks to regular mammogram screening, improved surgical techniques and better systemic treatments.
Whelan said his research is now tracking patients with the luminal A variant of breast cancer for 10 years to learn more about treatment efﬁcacy without the use of radiotherapy.
Call for Papers
ARO is seeking original case reports, research articles, and review articles on innovative topics offering practical applications in radiation oncology. Manuscripts undergo a double-blinded external peer review process, and there is no submission fee.
- First Clinical Results Published for 177Lu-rhPSMA-10.1 in mCRPC Trial
- Opaganib Shown to Protect Against Radiation-Induced Lung Inflammation
- Fusion Licenses Actinium-Based PSMA Targeted Radiotherapy From Heidelberg University and Euratom
- Future of Theranostics in Neurooncology Looks Promising With Recent Advancements
- First Cellular Therapy for Unresectable or Metastatic Melanoma Receives FDA Approval